Sanofi $SNY Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC lifted its holdings in Sanofi (NASDAQ:SNY) by 11.8% in the third quarter, HoldingsChannel reports. The firm owned 3,113,381 shares of the company’s stock after buying an additional 327,569 shares during the quarter. Natixis Advisors LLC’s holdings in Sanofi were worth $146,952,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Waterfront Wealth Inc. increased its position in shares of Sanofi by 0.4% during the third quarter. Waterfront Wealth Inc. now owns 49,119 shares of the company’s stock worth $2,463,000 after purchasing an additional 214 shares in the last quarter. HighPoint Advisor Group LLC increased its holdings in shares of Sanofi by 2.3% in the third quarter. HighPoint Advisor Group LLC now owns 9,923 shares of the company’s stock valued at $468,000 after purchasing an additional 226 shares during the period. HM Payson & Co. raised its position in Sanofi by 3.4% during the 3rd quarter. HM Payson & Co. now owns 7,248 shares of the company’s stock worth $342,000 after buying an additional 235 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. raised its holdings in Sanofi by 4.7% during the third quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 5,333 shares of the company’s stock worth $252,000 after purchasing an additional 238 shares in the last quarter. Finally, CreativeOne Wealth LLC raised its stake in shares of Sanofi by 2.8% during the 2nd quarter. CreativeOne Wealth LLC now owns 8,980 shares of the company’s stock worth $434,000 after buying an additional 241 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on SNY shares. Bank of America downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a report on Thursday, February 12th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a report on Monday, December 29th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. TD Cowen reaffirmed a “hold” rating on shares of Sanofi in a research report on Tuesday, December 30th. Finally, Barclays lowered shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $62.67.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $44.55 on Friday. The business’s 50-day simple moving average is $47.31 and its 200 day simple moving average is $48.46. Sanofi has a one year low of $44.00 and a one year high of $60.12. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09. The company has a market cap of $108.66 billion, a P/E ratio of 12.38, a PEG ratio of 1.15 and a beta of 0.45.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.